The anterior saphenous vein. Part 3. Systematic review of the literature and payor coverage policies. Endorsed by the American Vein and Lymphatic Society, the American Venous Forum and the International Union of Phlebology.

Autor:	Drgastin R; Inovia Vein Specialty Centers, Bend, OR, USA., Boyle EM; Inovia Vein Specialty Centers, Bend, OR, USA., Labropoulos N; Division of Vascular Surgery, Department of Surgery, Stony Brook Medicine, Stony Brook, NY, USA., Caggiati A; Department of Anatomy, University 'La Sapienza,', Rome, Italy., Gasparis A; Division of Vascular Surgery, Department of Surgery, Stony Brook Medicine, Stony Brook, NY, USA., Doganci S; Department of Cardiovascular Surgery, Gulhane School of Medicine, Health Sciences University, Ankara, Turkey., Meissner M; Division of Vascular Surgery, Department of Surgery, University of Washington Medical Center, Seattle, WA, USA.
Jazyk:	angličtina
Zdroj:	Phlebology [Phlebology] 2024 Jun; Vol. 39 (5), pp. 325-332. Date of Electronic Publication: 2024 Mar 25.
DOI:	10.1177/02683555231223281
Abstrakt:	Objective: The objective of this study is to systemically review the literature on Anterior Saphenous Vein (ASV) reflux treatment and insurance impediments to treatment coverage. Methods: A literature search was performed using a PRISMA framework. In addition, a cross-sectional analysis of insurance policies for ASV treatment was evaluated. Results: Published evidence and treatment considerations in the literature for ASV treatment are discussed. In 155 of 226 (68.6%) insurance policies reviewed coverage of ASV ablation was allowed while 62/226 (27.4%) did not specify coverage and 9/226 (4.0%) specified ASV treatment was not covered. Of the 155 that provide ASV coverage, 98 (62.2%) provide coverage with criteria such as requiring prior treatment of the great saphenous vein. Conclusions: Vein treatment experts should continue to advocate to insurance carriers to update their varicose vein treatment policies to reflect the substantial clinical evidence so that patients with ASV reflux can be appropriately treated. Competing Interests: Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RD, EB, AC, SD, and MM reports no conflicts. NL is a Consultant/Speaker with Philips, Medtronic, BD Bard, Boston Scientific; AG is a Consultant/Speaker: Medtronic, BD Bard, Boston Scientific.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu